VIP for IBD: Evidence Graded Review of Vasoactive Intestinal Peptide in Crohn's Disease and Colitis
What's breaking down if you have IBD (Crohn's / colitis)
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why VIP might help you
- You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.
- Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.
How these fit together
Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- VIP → immune / autonomic
What the evidence actually shows
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 5
- Claims tagged human evidence: 2
- Claims tagged preclinical (animal/lab): 3
- Claims tagged anecdotal: 1
- Reddit posts catalogued: 1
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 6
Quantified confidence (this ledger): 0.5 / 1.00 — low–moderate — mostly preclinical
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Vasoactive intestinal peptide as a laboratory supplement to clinical testing in inflammatory bowel disease (source s1)
Observational measurement of VIP in IBD patients.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Vasoactive intestinal peptide concentrations and immunocytochemistry in the colon of patients with Crohn's disease (source s2)
Tissue findings in Crohn's patients.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease (source s3)
Mouse TNBS colitis study showing reduced severity.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
Vasoactive Intestinal Peptide Nanomedicine for the Treatment of Inflammatory Bowel Disease (source s4)
Nanomedicine improved inflammation and barrier markers in mouse models.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
Vasoactive Intestinal Peptide Deficiency Is Associated With Dysbiosis and Altered Short-Chain Fatty Acid Levels in the Gastrointestinal Tract (source s5)
Reviews mixed preclinical and human expression data.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
What people say on Reddit
The peptide nobody talks about but everyone should: VIP — Reddit, r/Biohack_Blueprint (source s6)
Community comment on research relevance.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Evidence ledger 6 · tier-ranked · API
1 more ranked claim
Ask this article · 8 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.